It has been shown that in the concentration range where ginkgolide B does not produce cytotoxicity, gemcitabine in combination with ginkgolide B can enhance the effect of gemcitabine in killing resistant pancreatic cancer cells by inhibiting the PAFR/NF-κB pathway and reduce the resistance of pancreatic cancer to gemcitabine [59]. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.